Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. März 2018 10:33 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Pittsburgh, March 14, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
06. März 2018 14:04 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting

Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
12. Februar 2018 09:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference

PITTSBURGH, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment...
04. Januar 2018 08:05 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
08. November 2017 08:12 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Pittsburgh, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
04. November 2017 10:45 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery

Pittsburgh, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
30. Oktober 2017 08:12 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

PITTSBURGH, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
24. Oktober 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Pittsburgh, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
16. Oktober 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812

Pittsburgh, PA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
20. September 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference

PITTSBURGH, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...

Vorherige Seite